Carbacyclin, a PGI2 analog, is a prostacyclin (PGI2) receptor agonist and vasodilator with potent inhibitory platelet aggregation.

Carbacyclin acts as an inhibitor of platelet aggregation induced by ADP or collagen in vitro[2]. It also enhances CPT-1 mRNA expression through PPARδ, independent of the IP receptor signaling pathway. Furthermore, Carbacyclin, within the concentration range of 0.02 μM to 20 μM, activates the IP receptor signaling pathway through PKA, an effect that is blocked by H-89, a PKA inhibitor. Additionally, Carbacyclin, at concentrations ranging from 0.02 to 80 μM, increases PPRE promoter activity via PPARδ in cardiomyocytes, again independent of the IP receptor pathway[3].

Carbacyclin exhibits 0.03 times the activity of prostacyclin in inhibiting platelet aggregation in human, rabbit, or dog plasma [2]. Additionally, in the murine heart, Carbacyclin (100 μg, i.p.) induces CPT-1 mRNA expression [3].